Migraine

Branded Legacy, Inc. Innovates with Launch of the First 100% Clear Kava-Based Vaping Product on the Market

Retrieved on: 
Tuesday, February 6, 2024
Anxiety, Research, Migraine, Terpene, Therapy, Sleep, Pain, Safety, Headache, Cannabinoid, Alkaloid, Pain management, Health, Legacy, Teahouse

MELBOURNE, Fla., Feb. 6, 2024 /PRNewswire/ -- Branded Legacy, Inc. (OTC.PK: BLEG), a prominent Biotech company, proudly announces a major breakthrough in research and development efforts, leading the pack on new procedures for the extraction and refinement of kavalactones. In addition, The Alcannabist LLC, a wholly owned subsidiary of Branded Legacy , announced the official release of its new line of groundbreaking products designed to address diverse health and wellness needs.

Key Points: 
  • We were able to make a high purity extract that was completely translucent and very flavorful on the first day.
  • When we presented our extract to our kava suppliers, they asked to move forward immediately with a white label contract.
  • The Alcannabist's new products, which include: VapeRx Anti Anxiety, ElixRx Migraine/Headache Support, and Mood Mix Capsules, are now officially on the market.
  • The other three, ElixRx Plus Kava Anti Anxiety, ElixRx Plus Kava Sleep, and ElixRx Plus Kava Pain Management, will be included in their ElixRx line.

Danish dog owners are medicating their pets with unlicensed cannabis products – is it safe?

Retrieved on: 
Tuesday, February 6, 2024
Anxiety, Attention, Cannabis, Cannabidiol, Chronic pain, Travel, THC, Migraine, Research, Edible, Toxicity, Lethargy, Safety, Food, Dog, Oil, Cannabinoid, Osteoarthritis, Skin, Saliva, Thought, Pain management, Vomiting, Cat, Allergy, Health, Diarrhea, Pet, Medical imaging

Unsurprisingly, this trend has made its way to our pets, with a recent study suggesting that 38% of surveyed Danish dog owners routinely gave their pets some form of cannabis product.

Key Points: 
  • Unsurprisingly, this trend has made its way to our pets, with a recent study suggesting that 38% of surveyed Danish dog owners routinely gave their pets some form of cannabis product.
  • Previous studies suggest that 80% of dog owners in the US and Canada had bought cannabis products for their pet.
  • But, is CBD safe for our pets and could it be a useful addition to our pet’s healthcare regime?
  • Indeed, 36% of respondents in the Danish study indicated that they used cannabinoids for pain management in their pets.

Medicines360 and DKT WomanCare Announce Strategic Partnership to Expand Access to the Hormonal IUD Avibela™

Retrieved on: 
Wednesday, January 31, 2024
SAN, Nausea, Clinical trial, Perforation, Birth, Fibroid, Internal bleeding, Liver failure, Infection, Artery, Pelvic pain, DKT International, Jaundice, Anticoagulant, Blood pressure, Ovarian cyst, Woman, Acne, Organization, Partnership, Endometritis, Angioedema, History, Abscess, Contraindication, DKT, Peritonitis, Rash, Coagulopathy, Dyspareunia, Inflammatory cytokine, Adhesion, Vomiting, Bacterial vaginosis, Headache, Bowel obstruction, IUS, Uterus, STI, Breast cancer, Miscarriage, Patient, Fertility, Sepsis, Marketing, Risk, Stroke, Organ, Streptococcus, Hormone-sensitive cancer, Liver tumor, Cyst, Intrauterine device, GAS, Pregnancy, PID, Social marketing, Vaginitis, Migraine, Myocardial infarction, Health, Brain, Birth control

"As a global nonprofit pharmaceutical organization dedicated to expanding access to affordable reproductive health products for women, DKT WomanCare is an ideal partner for our organization," said Dr. Andrea Olariu, CEO of Medicines360.

Key Points: 
  • "As a global nonprofit pharmaceutical organization dedicated to expanding access to affordable reproductive health products for women, DKT WomanCare is an ideal partner for our organization," said Dr. Andrea Olariu, CEO of Medicines360.
  • “DKT WomanCare looks forward to leveraging our global partnerships and commercial relationships to ensure every woman, regardless of income, can access affordable, high-quality contraception.
  • As the supplier of AVIBELA, Medicines360 will focus on providing quality assurance and regulatory oversight, as well as ensuring sustainable product supply to DKT WomanCare and global procurement agencies.
  • Together, Medicines360 and DKT WomanCare will meet the growing demand for quality-assured, affordable hormonal IUDs and help build a robust and sustainable global contraceptive market.

Tonix Pharmaceuticals Announces Research Indicating Pre-Existing Fibromyalgia-Type Symptoms May Increase the Risk of Developing Long COVID

Retrieved on: 
Wednesday, January 31, 2024
Paper, Virus, Fibromyalgia, Chronic pain, University, Research, Low back pain, Food and Drug Administration, Faculty, Migraine, Patient, Irritable bowel syndrome, Pain, Endometriosis, Diagnosis, Central nervous system, COVID, Regardless, Doctor of Philosophy, Food, Back pain, Risk, Analytics, Chronic fatigue syndrome, Viral, NDA, Tonix Pharmaceuticals, Pharmaceutical industry

CHATHAM, N.J., Jan. 31, 2024 (GLOBE NEWSWIRE) -- Tonix Pharmaceuticals Holding Corp. (Nasdaq: TNXP) (Tonix or the Company), a biopharmaceutical company with marketed products and a pipeline of development candidates and currently focused on preparing a New Drug Application (NDA) for Tonmya (formerly TNX-102 SL, sublingual cyclobenzaprine HCl) for the management of fibromyalgia, today announced the online publication of a research paper in the Journal Pain. The article titled, “Chronic Overlapping Pain Conditions Increase the Risk of Long COVID Features, Regardless of Acute COVID Status,” by Bergmans, et al. 1, found that patients with pre-existing chronic overlapping pain conditions (COPCs) had an increased risk of being diagnosed with symptoms of Long COVID1. Faculty at the University of Michigan directed the research. Commentary on the article titled, “A step towards better understanding chronic overlapping pain conditions” by Fitzcharles, et al,2 is in the same issue of the journal.

Key Points: 
  • The article titled, “Chronic Overlapping Pain Conditions Increase the Risk of Long COVID Features, Regardless of Acute COVID Status,” by Bergmans, et al.
  • 1, found that patients with pre-existing chronic overlapping pain conditions (COPCs) had an increased risk of being diagnosed with symptoms of Long COVID1.
  • COPCs include fibromyalgia, chronic fatigue syndrome, migraine headache, irritable bowel syndrome, endometriosis and low back pain.
  • “Tonix is studying TNX-102 SL for the management of fibromyalgia (conditionally approved by U.S. Food and Drug Administration as “Tonmya”) and for fibromyalgia-type Long COVID.

Precautionary measures to address potential risk of neurodevelopmental disorders in children born to men treated with valproate medicines

Retrieved on: 
Sunday, February 4, 2024
Memory, Male, Spectrum, DSM-IV codes, European, Language, PRAC, European Medicines Agency, Birth, Patient, Child, Intellectual disability, Levetiracetam, EMA, Lamotrigine, Communication, Bipolar disorder, Epilepsy, Pregnancy, Disease, Migraine, Female, Risk, Neurodevelopmental disorder, Health care, Meta-analysis, Medicine, Committee, Father, Woman, Birth control

On 24 January 2024, the CMDh1 endorsed precautionary measures recommended by EMA’s safety committee (PRAC) for the treatment of male patients with valproate medicines. These…

Key Points: 


On 24 January 2024, the CMDh1 endorsed precautionary measures recommended by EMA’s safety committee (PRAC) for the treatment of male patients with valproate medicines. These…

Nexalin Technology Awarded Key Patent Related to its Non-Invasive, Frequency-Based Deep-Brain Stimulation Device – the Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System

Retrieved on: 
Tuesday, January 23, 2024
TACS, Patient, TBI, DSM-IV codes, Anxiety, Traumatic brain injury, Patent, Brain, Migraine, Insomnia, Television

The newly-issued patent, entitled “Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System,” covers the core technology utilized in the Company’s Gen-3 system, a proprietary and advanced waveform device that is designed to treat patients in a painless and undetectable manner.

Key Points: 
  • The newly-issued patent, entitled “Transcranial Alternating Current Dynamic Frequency Stimulation (TACS) System,” covers the core technology utilized in the Company’s Gen-3 system, a proprietary and advanced waveform device that is designed to treat patients in a painless and undetectable manner.
  • The Gen-3 system reflects state-of-the-art development of Nexalin’s Deep Intracranial Frequency Stimulation (DIFS®) technology, and a significant advancement to the predecessor Gen-1 system.
  • The Company’s technology uses a digital breakthrough in electrical waveforms to provide deep and painless brain neural stimulation.
  • Mark White, CEO of Nexalin Technology, stated, “This patent award for our non-invasive, deep-frequency stimulation device marks a major milestone for the Company, as it extends our IP protection through 2040.

HEALWELL AI Provides Corporate Update Highlighting its Growth and Value Creation Strategy and Recent Commercial Successes

Retrieved on: 
Tuesday, January 23, 2024
Real-World Evidence, Diabetes, RWE, Artificial intelligence, Dermatology, Patient, Vascular disease, Research, Hospital, Ophthalmology, EMR, Health, Knowledge, Intelligence, Migraine, AI, Heart failure, Algorithm, Growth, Digital, Artificial intelligence in healthcare, Software, Investment, Lung, TSX, Acquisition, AIDX, WELL, Physician, OTCQX, Prevalence, CDS, HEALTH, Data science, EHR, Pharmaceutical industry

HEALWELL subsidiary Pentavere has launched an innovative Real-World Evidence (RWE) product for Dermatologists to better support unmet patient needs.

Key Points: 
  • HEALWELL subsidiary Pentavere has launched an innovative Real-World Evidence (RWE) product for Dermatologists to better support unmet patient needs.
  • This product is called DERMAID and has already established its market presence with an immediate commercial win from a top 5 pharmaceutical company.
  • TORONTO, Jan. 23, 2024 (GLOBE NEWSWIRE) -- HEALWELL AI Inc. (“HEALWELL” or the “Company”) (TSX: AIDX, OTCQX: HWAIF), a healthcare technology company focused on AI and data science for preventative care, is pleased to provide a corporate update highlighting updates on the Company’s recent commercial successes and acquisition strategy.
  • Another key growth strategy for HEALWELL is to grow its operating businesses that work closely with the life sciences and pharmaceutical industries.

Apnimed Announces New Leadership Appointments as the Company Builds Its Commercial and Human Resource Capabilities in Support of AD109, a Potential Nighttime Oral Treatment for Obstructive Sleep Apnea

Retrieved on: 
Monday, January 22, 2024
Hamline University, Sleep, Ted Harding, Patient, Migraine, Therapy, COVID-19, Neurology, Obstructive sleep apnea, Culture, Standard of care, University, Commercial, Wake Forest University, Pfizer, MBA, Acquisition, Cornell University, Boehringer Ingelheim, Telecommunications, Merck, SVP, Growth, Pharmaceutical industry

The addition of Goodrich and Harding are critical new hires as Apnimed prepares to launch AD109 (aroxybutynin/atomoxetine), a potential nighttime oral treatment currently in Phase 3 that could transform the treatment paradigm for millions of OSA patients.

Key Points: 
  • The addition of Goodrich and Harding are critical new hires as Apnimed prepares to launch AD109 (aroxybutynin/atomoxetine), a potential nighttime oral treatment currently in Phase 3 that could transform the treatment paradigm for millions of OSA patients.
  • Graham Goodrich has an extensive track record of commercial success in launching and marketing transformative brands.
  • After a successful launch and achieving category leadership, Pfizer acquired the Biohaven Migraine franchise assets and capabilities in October 2022 for $11.6 billion.
  • I’m excited to help further develop a company that will have such a profound impact on the lives of OSA patients,” Harding said.

Optinose Announces the Publication of ReOpen Phase 3 Clinical Trial Program Evaluating XHANCE in the Journal of Allergy and Clinical Immunology: In Practice

Retrieved on: 
Thursday, January 18, 2024
Senior, Chronic pain, Patient, Sciatica, Ear, Incidence, Polyp (medicine), ENT, Nosebleed, Sinusitis, Doctor of Pharmacy, Migraine, Randomness, Heart, OPTN, Quality of life, Medicine, Nose, Journal, Disease, Pressure, Drainage, FDA, Inflammation, MPH, Headache, Fluticasone, Pharmaceutical industry

YARDLEY, Pa., Jan. 18, 2024 (GLOBE NEWSWIRE) --  Optinose (NASDAQ:OPTN), a pharmaceutical company focused on patients treated by ear, nose and throat (ENT) and allergy specialists, today announced peer-reviewed publication of results from both ReOpen1 and ReOpen2 in the Journal of Allergy and Clinical Immunology: In Practice1.

Key Points: 
  • The ReOpen program evaluated XHANCE for treatment of adults with chronic sinusitis (chronic rhinosinusitis).
  • “Patients with chronic sinusitis often suffer for years and may use multiple over-the-counter treatments in a search for ways to alleviate their symptoms.
  • Chronic sinusitis is also common: data suggests it is one of the top diagnoses in adult outpatient physician visits.
  • The safety profile and tolerability of XHANCE for patients in the ReOpen trials was generally consistent with its currently labeled safety profile.

Takeda’s GAMMAGARD LIQUID® Approved by U.S. FDA for Adults with Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)

Retrieved on: 
Monday, January 29, 2024
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, CIDP, Rasch, Patient, Chronic inflammatory demyelinating polyneuropathy, Facial muscles, Paresthesia, Common, Leukopenia, Neutropenia, Anemia, Migraine, University, Abdominal pain, Chills, Head, Recombinant, Tremor, Food, Safety, Antibody, Pain, Neurology, Weakness, Headache, IVIG, Somnolence, Vomiting, Trial of the century, Dizziness

“Together with the recent HYQVIA approval in the U.S., we can now offer induction and maintenance therapy options to adults living with CIDP that may accommodate their personal treatment needs.”

Key Points: 
  • “Together with the recent HYQVIA approval in the U.S., we can now offer induction and maintenance therapy options to adults living with CIDP that may accommodate their personal treatment needs.”
    The approval is based on results from a prospective, open-label, single-arm, multicenter clinical study (ADVANCE-CIDP 2) that evaluated the efficacy and safety of GAMMAGARD LIQUID in adults with CIDP who developed a relapse in the randomized, double-blinded, placebo-controlled study evaluating efficacy, safety and tolerability of HYQVIA (ADVANCE-CIDP 1) in adults with CIDP.
  • Efficacy in ADVANCE-CIDP 2 was based on responder rate, where a responder was defined as a subject who demonstrated an improvement of functional disability.
  • The responder rate was 94.4% (N=18, 95% CI: 74.2% to 99.0%).
  • “Because CIDP is a progressive and complex disease, multiple treatment options are needed, and clinicians now have an additional therapy that can help adults with CIDP manage their disease.”
    GAMMAGARD LIQUID is the only IVIG with multiple neuromuscular disorder indications in the U.S. since it is now approved for CIDP and it is the only FDA-approved IVIG to treat multifocal motor neuropathy as a maintenance therapy to improve muscle strength and disability in adults.1 It is also indicated in the U.S. as a replacement therapy for people two years of age or older living with primary immunodeficiency.1